Latest period
$143B
YoY change
+4.1%
5Y CAGR
-0.0%
Peak year (FY2020)
$137B
Latest annual
$137B
Total Liabilities history chart for AbbVie (ABBV) from 2016 to 2025
Latest: $137B
Total Liabilities growth chart for AbbVie (ABBV) from 2016 to 2025
Latest: +4.1%
Total Liabilities history table for AbbVie (ABBV) from 2010 to 2025
| FY2025 | $137B | +4.1% | +$5.39B | ||
| FY2024 | $132B | +6.0% | +$7.48B | ||
| FY2023 | $124B | +2.3% | +$2.8B | ||
| FY2022 | $122B | -7.3% | -$9.58B | ||
| FY2021 | $131B | -4.6% | -$6.38B | ||
| FY2020 | $137B | +41.3% | +$40.2B | ||
| FY2019 | $97.3B | +43.5% | +$29.5B | ||
| FY2018 | $67.8B | +3.2% | +$2.11B | ||
| FY2017 | $65.7B | +6.9% | +$4.23B | ||
| FY2016 | $61.5B | +25.2% | +$12.4B | ||
| FY2015 | $49.1B | +90.5% | +$23.3B | ||
| FY2014 | $25.8B | +4.3% | +$1.07B | ||
| FY2013 | $24.7B | +4.5% | +$1.06B | ||
| FY2012 | $23.6B | +211.6% | +$16.1B | ||
| FY2011 | $7.59B | +39.7% | +$2.16B | ||
| FY2010 | $5.43B | — | — |
- FY2025$137B+4.1%
- FY2024$132B+6.0%
- FY2023$124B+2.3%
- FY2022$122B-7.3%
- FY2021$131B-4.6%
- FY2020$137B+41.3%
- FY2019$97.3B+43.5%
- FY2018$67.8B+3.2%
- FY2017$65.7B+6.9%
- FY2016$61.5B+25.2%
- FY2015$49.1B+90.5%
- FY2014$25.8B+4.3%
- FY2013$24.7B+4.5%
- FY2012$23.6B+211.6%
- FY2011$7.59B+39.7%
- FY2010$5.43B—
Total Liabilities values are taken from AbbVie's reported balance sheets (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Total Liabilities at AbbVie (ABBV)
According to AbbVie's latest reported financial statements, the company's latest reported total liabilities is $143B. Total liabilities sum everything the company owes at the end of each reporting period — accounts payable, accrued expenses, debt, lease obligations, and other claims — as filed on the balance sheet. Compare with total assets and total equity for solvency context.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
AbbVie (ABBV) most recent annual total liabilities stands at $137B (2025) – edged up 4.1% year-over-year.
Across 2020–2025 (5 years), AbbVie total liabilities produced a CAGR of -0.0% – with a net decline across the window.
Across the available history, total liabilities reached its high of $137B in 2020 and its low of $5.43B in 2010.
AbbVie Total Liabilities by Year
AbbVie Total Liabilities 2025: $137B
AbbVie posted total liabilities of $137B in 2025, edged up 4.1% from 2024.
AbbVie Total Liabilities 2024: $132B
In 2024, AbbVie reported total liabilities of $132B, grew 6.0% from 2023.
AbbVie Total Liabilities 2023: $124B
AbbVie total liabilities in 2023 was $124B, edged up 2.3% from 2022.
AbbVie Total Liabilities 2022: $122B
2022's total liabilities for AbbVie came in at $122B, declined 7.3% below 2021.
AbbVie Total Liabilities 2021: $131B
AbbVie total liabilities in 2021 was $131B.
See more financial history for AbbVie (ABBV).
Sector peers by Total Liabilities
Healthcare peers of AbbVie (ABBV), ranked by their latest total liabilities
| $208B | |
| $118B | |
| $85.9B | |
| $84.2B | |
| $81.9B | |
| $56.8B | |
| $54.9B | |
| $33.9B |
- $85.9B
- $84.2B
- $81.9B
- $54.9B
Frequently asked questions
AbbVie (ABBV) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
How this company returns cash to shareholders — buybacks, dividends, and stock splits.